@article {Keating:2007:1172-7047:695,
	author = "Keating, Gillian M.",
	author = "Robinson, Dean M.",
	title = "Spotlight on Quetiapine in Bipolar Depression",
	journal = "CNS Drugs",
	volume = "21",
	year = "2007",
	abstract = "Quetiapine (Seroquel<SUP>&#174;</SUP>) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life. Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.",
	pages = "695-697(3)",
	url = "http://www.ingentaconnect.com/content/adis/cns/2007/00000021/00000008/art00008"
}